[Effect of prestarium in patients with chronic heart failure].
The main active factor in the progression of chronic heart failure (CHF) is a renin-angiotensin system (RAS), namely its main hormone angiotensin-II, which induces variety effects of given neurohormonal system (vasoconstriction, increased arterial pressure, hypertrophy, and fibrosis). It diminishes the role of the etiological factor and determines the quality to life and prognosis of the disease. Prestarium as an angiotensin-converting enzyme inhibitor significantly improved the functional class (FC) and increased the 6 min distance of walking. In addition, patients reported a slight improvement of life quality. Prestarium consistently improved all major parameters of central hemodynamics, with a statistically significant improvement of end systolic volume and LV ejection fraction by 3 months. Therefore Prestarium improved the clinical status and exerted beneficial effects on LV volumes and LV contractile capability in patients with CHF.
Abashidze
T B
TB
Lortkipanidze
R M
RM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001146:Arrhythmia, Sinus / Q000453:epidemiology; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology
D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril